Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis

Linda S Snyder, R. I. Heigh, M. L. Anderson

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Cyclophosphamide is widely used in the treatment of many vasculitides. Hepatotoxicity associated with such therapy is uncommon but possible. Herein we describe a well-substantiated case of cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Physicians should be aware of this potentially serious reaction when cyclophosphamide therapy is initiated. Baseline liver function tests and periodic assessment are recommended during treatment with cyclophosphamide.

Original languageEnglish (US)
Pages (from-to)1203-1204
Number of pages2
JournalMayo Clinic Proceedings
Volume68
Issue number12
StatePublished - 1993

Fingerprint

Granulomatosis with Polyangiitis
Cyclophosphamide
Liver Function Tests
Therapeutics
Vasculitis
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. / Snyder, Linda S; Heigh, R. I.; Anderson, M. L.

In: Mayo Clinic Proceedings, Vol. 68, No. 12, 1993, p. 1203-1204.

Research output: Contribution to journalArticle

Snyder, Linda S ; Heigh, R. I. ; Anderson, M. L. / Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. In: Mayo Clinic Proceedings. 1993 ; Vol. 68, No. 12. pp. 1203-1204.
@article{a1d2c79e6998433caae51519fc9eb62b,
title = "Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis",
abstract = "Cyclophosphamide is widely used in the treatment of many vasculitides. Hepatotoxicity associated with such therapy is uncommon but possible. Herein we describe a well-substantiated case of cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Physicians should be aware of this potentially serious reaction when cyclophosphamide therapy is initiated. Baseline liver function tests and periodic assessment are recommended during treatment with cyclophosphamide.",
author = "Snyder, {Linda S} and Heigh, {R. I.} and Anderson, {M. L.}",
year = "1993",
language = "English (US)",
volume = "68",
pages = "1203--1204",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "12",

}

TY - JOUR

T1 - Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis

AU - Snyder, Linda S

AU - Heigh, R. I.

AU - Anderson, M. L.

PY - 1993

Y1 - 1993

N2 - Cyclophosphamide is widely used in the treatment of many vasculitides. Hepatotoxicity associated with such therapy is uncommon but possible. Herein we describe a well-substantiated case of cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Physicians should be aware of this potentially serious reaction when cyclophosphamide therapy is initiated. Baseline liver function tests and periodic assessment are recommended during treatment with cyclophosphamide.

AB - Cyclophosphamide is widely used in the treatment of many vasculitides. Hepatotoxicity associated with such therapy is uncommon but possible. Herein we describe a well-substantiated case of cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Physicians should be aware of this potentially serious reaction when cyclophosphamide therapy is initiated. Baseline liver function tests and periodic assessment are recommended during treatment with cyclophosphamide.

UR - http://www.scopus.com/inward/record.url?scp=0027501440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027501440&partnerID=8YFLogxK

M3 - Article

C2 - 8246624

AN - SCOPUS:0027501440

VL - 68

SP - 1203

EP - 1204

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 12

ER -